Holen Sie sich die Stockscreener-App
0.4021
4.68%
-0.0189
Schlusskurs vom Vortag:
$0.421
Offen:
$0.4283
24-Stunden-Volumen:
726.84K
Relative Volume:
0.14
Marktkapitalisierung:
$33.40M
Einnahmen:
$297.50K
Nettoeinkommen (Verlust:
$-72.19M
KGV:
-0.2348
EPS:
-1.7127
Netto-Cashflow:
$-54.39M
1W Leistung:
-3.07%
1M Leistung:
-18.10%
6M Leistung:
-61.41%
1J Leistung:
-72.89%
1-Tages-Spanne:
$0.4006
$0.4283
1-Wochen-Bereich:
$0.4006
$0.461
52-Wochen-Spanne:
$0.3801
$3.39
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Firmenname
Outlook Therapeutics Inc
Sektor
Branche
Telefon
(609) 619-3990
Adresse
111 S. WOOD AVENUE, ISELIN, NJ
Compare OTLK vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
0.4021 | 34.97M | 297.50K | -72.19M | -54.39M | -1.7127 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.70 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.79 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
705.66 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.82 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.42 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-08-28 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-12-02 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-03-27 | Hochstufung | BTIG Research | Neutral → Buy |
| 2024-02-15 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2024-01-25 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-12-27 | Hochstufung | CapitalOne | Equal Weight → Overweight |
| 2023-08-31 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2023-08-31 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-08-30 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-08-30 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-08-30 | Herabstufung | CapitalOne | Overweight → Equal Weight |
| 2023-08-30 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-07-13 | Eingeleitet | CapitalOne | Overweight |
| 2023-04-03 | Eingeleitet | Guggenheim | Buy |
| 2023-02-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-10-31 | Eingeleitet | BTIG Research | Buy |
| 2022-09-13 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-09-11 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2019-05-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-04-22 | Eingeleitet | Ascendiant Capital Markets | Buy |
Alle ansehen
Outlook Therapeutics Inc Aktie (OTLK) Neueste Nachrichten
Outlook Therapeutics Announces Board Resignation and Size Reduction - TipRanks
Ascendiant Capital Lowers Price Target for Outlook Therapeutics (OTLK) | OTLK Stock News - GuruFocus
Outlook Therapeutics discusses FDA meeting on bevacizumab drug - Investing.com Nigeria
Published on: 2026-03-10 21:03:39 - baoquankhu1.vn
Key facts: Outlook Therapeutics Engages FDA on ONS-5010 Approval Pathways - TradingView
Outlook Therapeutics discusses FDA meeting on bevacizumab drug By Investing.com - Investing.com Australia
Outlook Therapeutics Updates FDA Path For ONS-5010 Following Type A Meeting - Nasdaq
FDA meeting prompts new ONS-5010 update, Outlook Therapeutics outlines - Traders Union
Outlook Therapeutics (OTLK) Advances Towards FDA Approval for ONS-5010 - GuruFocus
Outlook Therapeutics advances FDA dialogue on ONS-5010 approval - TipRanks
Outlook Therapeutics Offers Update After FDA Meeting About ONS-5010/LYTENAVA - marketscreener.com
Outlook Therapeutics provides update following Type A meeting with FDA - marketscreener.com
Outlook Therapeutics Provides Update Following Type A Meeting With FDA - TradingView
Outlook Therapeutics (Nasdaq: OTLK) details FDA Type A meeting on ONS-5010 - Stock Titan
Outlook Therapeutics Provides Update Following Type A - GlobeNewswire
Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA (bevacizumab-vikg) - Bitget
Can Outlook Therapeutics Inc reach all time highs this yearJuly 2025 Summary & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Risk On: Will Outlook Therapeutics Inc benefit from AI trendsJuly 2025 Spike Watch & Precise Buy Zone Identification - baoquankhu1.vn
OTLK Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Buyback Watch: Is Old Point Financial Corporation a good ESG investment2025 EndofYear Setup & Daily Profit Focused Screening - baoquankhu1.vn
OTLKW News Today: Stay Updated with the Latest Outlook Therapeutics, Inc.Se News in Real Time - Meyka
Aug Macro: Will Outlook Therapeutics Inc benefit from government policyMarket Sentiment Summary & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Key facts: Outlook Therapeutics Faces Nasdaq Compliance Deadline; Signs Deal with Mediconsult AG - TradingView
Outlook Therapeutics Signs Exclusive Distribution Deal With Mediconsult for Lytenava - marketscreener.com
Outlook Therapeutics (OTLK) Secures Swiss Distribution Deal for Lytenava - GuruFocus
Outlook Therapeutics, Inc. accelerates its European market expansion plan through partnerships, with its innovative drug Lytenava expected to officially enter the Swiss market in 2027. - Bitget
Can Outlook Break The Cycle With Fresh FDA Meeting On Ophthalmic Bevacizumab? - Citeline News & Insights
Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland - The Manila Times
Outlook Therapeutics Reports Q1 Fiscal Year 2026 Financial Results - VisionMonday.com
Outlook Therapeutics (OTLK) Maintains Neutral Rating According t - GuruFocus
Outlook Therapeutics Faces Nasdaq Minimum Bid Price Noncompliance - TipRanks
Outlook Therapeutics, Inc. accelerates its European market expansion plans through partnerships, with its innovative drug Lytenava expected to officially enter the Swiss market in 2027. - Bitget
Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA (bevacizumab gamma) in Switzerland - Bitget
Outlook Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Key facts: Outlook Therapeutics reports $1.2M loss; LYTENAVA launched in Europe - TradingView
OTLK: Analyst Maintains Neutral Rating and Price Target | OTLK S - GuruFocus
Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update - The Globe and Mail
Outlook Therapeutics, Inc. SEC 10-Q Report - TradingView
OTLK: Net loss of $23.1M, negative revenue, and liquidity risks amid delayed US approval for LYTENAVA - TradingView
Outlook Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2025 - marketscreener.com
OTLK: European sales of LYTENAVA doubled, but US approval for ONS-5010 remains uncertain - TradingView
Outlook Therapeutics swings to Q1 net loss - TradingView
Outlook Therapeutics Advances LYTENAVA™ Expansion in Europe with Launch Scheduled for Austria and Regulatory Update for ONS-5010 in the U.S. - Quiver Quantitative
Outlook Therapeutics Earnings Report: Q1 Overview - Benzinga
Published on: 2026-02-16 11:51:16 - mfd.ru
Sell Signal: Can Outlook Therapeutics Inc. stock maintain growth trajectoryDay Trade & Free Accurate Trade Setup Notifications - mfd.ru
OTLK Stock Price, Forecast & Analysis | OUTLOOK THERAPEUTICS INC (NASDAQ:OTLK) - ChartMill
Outlook Therapeutics Seeks FDA Meeting on ONS-5010 BLA - The Globe and Mail
SPHERA FUNDS MANAGEMENT LTD. Acquires Significant Stake in Outlo - GuruFocus
Key facts: Outlook Therapeutics Seeks FDA Meeting on ONS-5010 Issues - TradingView
IPO Launch: What drives Renasant Corporations stock priceQuarterly Earnings Summary & Daily Growth Stock Tips - baoquankhu1.vn
Finanzdaten der Outlook Therapeutics Inc-Aktie (OTLK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):